CCL4 Antagonist Inhibits Vascular Aging via CCR5 Receptor Blockade

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is currently no effective strategy to inhibit vascular aging, which leads to decreased physical and cardiovascular functions and increased risk of fatal diseases such as myocardial infarction and stroke.

Innovation Solution

The use of a CCL4 antagonist in a pharmaceutical composition to inhibit vascular aging by reducing CCL4 levels, inhibiting its binding with receptors, or a combination thereof, thereby resisting the aging of vascular endothelial cells and enhancing angiogenesis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If CCL4 antagonist is administered to inhibit vascular aging, then vascular endothelial cell aging is resisted and angiogenesis is enhanced, but the mechanism and efficacy need further clinical verification

Engineering Contradiction:

Improveefficacy of inhibiting vascular agingVSAvoidcomplexity of treatment strategy

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses CCL4 antagonist as an intermediary substance to block the interaction between CCL4 and its receptor CCR5 on vascular endothelial cells. This mediator approach allows inhibition of the CCL4-CCR5 signaling pathway that promotes vascular aging, thereby resisting endothelial cell aging and enhancing angiogenesis without requiring direct modification of cellular structures or complex multi-component systems

Inventive Principle:

Principle #24Intermediary (Mediator)

2Stability of the object's composition

If CCL4 levels are reduced to inhibit vascular aging, then vascular elasticity is maintained and cardiovascular function is improved, but the specificity of CCL4 inhibition needs to be ensured

Engineering Contradiction:

Improvevascular elasticityVSAvoidoff-target effects of CCL4 inhibition

Core Design Contradiction:

Stability of the object's compositionVSObject-affected harmful factors

Solution Approach 1:

The patent employs antagonists with high specificity for CCL4 or its receptor CCR5, ensuring that the inhibition occurs locally at the target binding site without affecting other chemokine-receptor interactions. This localized specificity maintains vascular elasticity and prevents cardiovascular dysfunction while avoiding off-target effects on other physiological processes that depend on different chemokine signaling pathways

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The CCL4 antagonist effectively regulates aging factors, inflammatory factors, and angiogenic factors, thereby inhibiting vascular aging and improving the ability of angiogenesis.

Implementation Method 1

inhibiting a binding activity of the CCL4 with a receptor thereof

Methodology Applied

Scientific EffectBinding:

Data Source

PatentUS20250163141A1CCL4 antagonist for inhibiting vascular aging

Publication Date: 2025.05.22 NAT YANG MING CHIAO TUNG UNIV

AI summary

Provided is a method for inhibiting vascular aging in a subject in need thereof by administering a pharmaceutical composition including a CCL4 antagonist. The CCL4 antagonist inhibits vascular aging by reducing a CCL4 level, inhibiting a binding activity of CCL4 with a receptor thereof, or a combination thereof.